YGYiyi Gong

Yiyi Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yiyi Gong has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Weibo Xia

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    12 shared publications
  • Xiaoping Xing

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    12 shared publications
  • Qianqian Pang

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    11 shared publications
  • Ou Wang

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    9 shared publications
  • Xiang Li

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    9 shared publications
  • Yan Jiang

    Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing 100730

    9 shared publications

Latest Publications

  • Open Access

    Multiplatform Urinary Metabolomics For Diagnostic Discrimination Of Autism And Attention-Deficit/Hyperactivity Disorder: An Observational Study

    by Yiyi Gong, Xin You, Yangzhige He, Xinjie Xu, Huinuo Wang

    Background: Autism and attention-deficit/hyperactivity disorder (ADHD) are common neurodevelopmental conditions with overlapping behavioral features that complicate differential diagnosis. Urinary metabolomics offers a non-invasive approach to developing objective biomarkers that complement clinical assessment.Methods: We analyzed urine from 219 children (110 with autism, 24 with ADHD, and 85 healthy controls) using untargeted liquid chromatography–mass spectrometry and gas chromatography–mass spectrometry. The autism and control participants in the untargeted cohort were divided into discovery (47 and 34) and independent validation (63 and 51) cohorts according to recruitment date, whereas the ADHD participants were included for comparative analyses. A three-metabolite panel was selected using machine-learning methods in the discovery cohort and evaluated in the independent untargeted validation cohort. The panel was subsequently assessed using targeted metabolomics in an additional independent cohort of 46 participants (27 with autism, nine with ADHD, and ten controls).Findings: Linoleamide, androsterone sulfate, and arachidic acid formed a three-metabolite panel. For autism versus controls, the area under the curve (AUC) was 0.880 (95% CI 0.788-0.956) in discovery and 0.923 (0.875-0.988) in validation. Exploratory AUCs were 0.811 for ADHD versus controls and 0.787 for autism versus ADHD. Corresponding targeted-cohort AUCs were 0.84, 0.80, and 0.70.Interpretation: A compact urinary metabolite panel identified by multiplatform metabolomics and machine learning may support non-invasive differential assessment of autism and ADHD. Its compact composition and performance provide a practical basis for developing non-invasive adjuncts to diagnostic assessment.

  • Open Access

    Clinical characteristics of tumor-induced osteomalacia lesions in the neurocranium and intracranial structures

    by Yushuo Wu, Xiang Li, Zhiqin Xu, Wei Lv, Zhixiang Wang, Xiaolin Ni, Qianqian Pang, Ruizhi Jiajue, Yue Chi, Wei Liu, et al.

    Background: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) secretion. However, TIO lesions located in the neurocranium (NC) and intracranial (IC) structures remain poorly characterized. Objective: To characterize the clinical features of TIO lesions in NC and IC structures and to compare them with those located in the sinuses. Methods: This retrospective study included patients diagnosed with TIO who underwent tumor resection at Peking Union Medical College Hospital between January 2016 and December 2023. Patients with lesions in NC and IC structures were defined as the study group, while those with sinus lesions served as the control group. Clinical characteristics, biochemical parameters, and surgical outcomes were systematically analyzed and compared between groups. Results: TIO lesions in NC and IC structures were distributed across the skull base, temporal region, sellar region, frontal lobe, and occipital region. Compared with sinus lesions, patients with NC and IC lesions showed comparable clinical and biochemical profiles but exhibited significantly worse outcomes, including higher rates of non-remission and tumor recurrence. These findings suggest increased difficulty in complete tumor resection and disease control in this subgroup. Conclusion: TIO lesions in NC and IC structures are associated with poorer surgical outcomes and higher recurrence rates despite similar baseline characteristics. These results highlight the need for improved localization strategies and tailored management approaches for this challenging subgroup.

  • Open Access

    Relationship Between Serum Nell‐1 Level and Bone Geometry, Bone Microarchitecture in Chinese Postmenopausal Women

    by Yiyi Gong, Yushuo Wu, Xiang Li, Xiaosen Ma, Xiaolin Ni, Wei Liu, Lijia Cui, Yue Chi, Ruizhi Jiajue, Qianqian Pang, et al.

    Purpose: Neural EGF‐like 1 (Nell‐1), originally implicated in craniosynostosis, has been identified as a key regulator in osteogenic processes. While preclinical data were encouraging, clinical studies correlating serum Nell‐1 levels with osteoporosis remain scarce. This study aims to investigate the relationship between circulation Nell‐1 level and bone turnover markers, bone mineral density (BMD), bone microstructure, muscle strength, fall risk, and fractures in Chinese postmenopausal women. Methods: Serum Nell‐1 levels were measured in 123 Chinese postmenopausal women. Muscle function was evaluated through grip strength tests, the Short Physical Performance Battery (SPPB), and the Timed Up and Go (TUG) test. Dual‐energy X‐ray absorptiometry was used to assess areal bone mineral density (aBMD), lumbar trabecular bone score (TBS), and muscle mass. High‐resolution peripheral quantitative computed tomography (HR‐pQCT) was applied to determine volumetric bone mineral density (vBMD), analyze bone microarchitecture, and estimate bone strength. Result: Postmenopausal women with higher serum Nell‐1 levels had higher aBMD and total volumetric bone mineral density (Tot.vBMD) at the distal tibia, larger cortical area (Ct.Ar) and thicker cortical thickness (Ct.Th) at the distal tibia, and higher bone strength. There was a significant negative association between serum Nell‐1 levels and C‐terminal cross‐linking telopeptide of type I collagen (β‐CTX), while no significant correlations were observed between serum Nell‐1 levels and muscle mass or function. Conclusion: Postmenopausal women with higher serum Nell‐1 levels exhibited higher BMD and bone strength, indicating its potential as a therapeutic invention for osteoporosis.

  • Open Access

    Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis

    by Qianqian Pang, Xuan Qi, Yue Chi, Ruizhi Jiajue, Li Zhang, Lijia Cui, Ou Wang, Mei Li, Xiaoping Xing, Yan Jiang, et al.

    Context: Primary hypertrophic osteoarthropathy (PHO) is a rare genetic disorder characterized by skeletal and skin abnormalities. Genetic defects in prostaglandin E2 (PGE2) metabolism are known to cause PHO. However, the global impact and clinical significance of eicosanoids and oxylipins beyond PGE2 remain to be elucidated. Objective: This study aimed to investigate oxylipin networks in PHO, including the 2 subtypes, PHOAR1 and PHOAR2, and examine their associations with clinical characteristics. Methods: We conducted a targeted metabolomic study involving 16 patients with PHO and 16 age- and sex-matched healthy controls. Serum samples were collected at the time of diagnosis. Metabolites were quantified using ultra-high–performance liquid chromatography-tandem mass spectrometry. Results: Laboratory analyses confirmed elevated levels of PGE2 in patients with PHO, consistent with the established pathogenesis. About 60 oxidized lipid metabolites were identified, with 19 differentially expressed in PHO. Besides the COX/PGE2 pathway, the lipoxygenase-mediated pathway was also involved in PHO. The metabolites 5-OxoETE, 15-OxoETE, 8S,15S-DiHETE, PGE2, 11β-PGE2, PGB2, LTB4, and LTE4 were significantly altered. Correlation analyses revealed associations between oxylipin metabolites and clinical features, including bone microarchitecture. Notably, the study highlighted differences in the oxylipin metabolite profiles between patients with PHOAR1 and patients with PHOAR2, suggesting distinct metabolic signatures for each subtype. Conclusion: Our study indicated a significant perturbation in oxylipin metabolism among patients with PHO, with distinct metabolic signatures observed between PHOAR1 and PHOAR2. The disruption extended beyond the metabolism of PGE2. It encompassed a broader alteration across the polyunsaturated fatty acid metabolism spectrum, including various eicosanoids and oxylipins. Our work provided a comprehensive understanding of the pathogenesis of PHO, and underscored the potential for subtype-specific therapeutic interventions.


  • Gastrodin alleviates diabetic peripheral neuropathy by regulating energy homeostasis via activating AMPK and inhibiting MMP9

    by Wei Song, Bingjia Zhao, Qunli Wu, Yiyi Gong, Yifan Jia, Yamin Zhang, Yunshuang Yang, Bo Zhang, Xiaochun Liang, Qian Zhang


  • Identification of Rare and Novel PHEX Variants in X-linked Hypophosphatemia

    by Xiaosen Ma, Qianqian Pang, Yiyi Gong, Xiang Li, Wei Liu, Yan Jiang, Ou Wang, Mei Li, Xiaoping Xing, Weibo Xia

    Context X-linked hypophosphatemia (XLH) is a rare metabolic bone disease caused by inactivation mutations in the PHEX gene. Despite the extensive number of reported PHEX variants, only a few cases of chromosomal abnormalities have been documented. Objective We aimed to identify the pathogenic variants in six unrelated families with a clinical diagnosis of XLH and to propose a genetic workflow for hypophosphatemia patients suspected of XLH. Methods Multiple genetic testing assays were used to analyze the six families’ genetic profiles, including whole exome sequencing, multiplex ligation-dependent probe amplification, whole genome sequencing, reverse transcript polymerase chain reaction, Sanger sequencing, and karyotyping. Results The study identified six novel pathogenic variants, including one mosaic variant (exon 16-22 deletion), three chromosomal abnormalities (46, XN, inv[X][pter→p22.11::q21.31→p22.11::q21.31 →qter], 46, XN, inv[X][p22.11p22.11], and XXY), a nonclassical intron variant (NM_000444.6, c.1701_31A > G), and a deletion variant (NM_000444.6, c.64_5464-186 del5215) of PHEX. Additionally, a genetic testing workflow was proposed to aid in diagnosing patients suspected of XLH. Conclusion Our research expands the mutation spectrum of PHEX and highlights the significance of utilizing multiple genetic testing methods to diagnose XLH.


  • Response to Letter to the Editor From Judit Tőke and Miklós Tóth: “Shift in Calcium From Peripheral Bone to Axial Bone After Tumor Resection in Patients With Tumor-Induced Osteomalacia”

    by Xiaolin Ni, Zaizhu Zhang, Wenmin Guan, Yue Chi, Xiang Li, Yiyi Gong, Qianqian Pang, Wei Yu, Huanwen Wu, Li Huo, et al.

    Xiaolin Ni, Ph.D, Zaizhu Zhang, M.D, Wenmin Guan, M.D, Yue Chi, M.D, Xiang Li, M.D, Yiyi Gong, Ph.D, Qianqian Pang, Ph.D, Wei Yu, M.D, Huanwen Wu, M.D, Li Huo,

  • Shift in Calcium From Peripheral Bone to Axial Bone After Tumor Resection in Patients With Tumor-Induced Osteomalacia

    by Xiaolin Ni, Zaizhu Zhang, Wenmin Guan, Yue Chi, Xiang Li, Yiyi Gong, Qianqian Pang, Wei Yu, Huanwen Wu, Li Huo, et al.

    Context Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive production of fibroblast growth factor 23 (FGF23) by a tumor. After successful tumor resection, patients could recover from hypophosphatemia quicky. However, data on the changes in bone mineral density (BMD) and microstructure in the short term after surgery remained unclear. Objectives To investigate the postoperative changes in BMD and microstructure in both peripheral and axial bone in TIO patients. Design, Setting, Participants and Main outcome measurements We evaluated BMD and microarchitecture in 22 TIO patients using high-resolution peripheral quantitative computed tomography (HR-pQCT) and dual-energy X-ray absorptiometry (DXA) before and 3 months after surgery in this retrospective study. Results In this study, a total of 22 TIO patients who had recovered serum phosphate levels postoperatively were enrolled. After surgery, areal BMD (aBMD) increased by 21.6% in the femoral neck, by 18.9% in the total hip, and by 29.5% in the lumbar spine. Moreover, TBS increased by 14.1% (all p < 0.001). In contrast, trabecular or cortical volumetric BMD (vBMD), and microstructure of trabecular bone (trabecular number, separation and bone volume ratio) and cortical bone (cortical thickness and porosity) at the distal radius or tibia were further deteriorated. Correlation analyses found that both changes in femoral neck and total hip aBMD were conversely associated with changes in trabecular vBMD and bone volume ratio, while positively correlated with change in trabecular separation at the distal radius. Conclusions Although aBMD and microstructure in the axial bone were improved, vBMD and microstructure in the peripheral bone were further impaired shortly after surgery. Correlation of improvement of aBMD in the total hip and femoral neck with deterioration of vBMD and microstructure at the distal radius indicated shift in calcium from the peripheral bone to the axial bone in the short term after tumor resection in TIO patients.


  • Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study

    by Xiang Li, Yiyi Gong, Qi Zhang, Xiaolin Ni, Qianqian Pang, Yue Chi, Ruizhi Jiajue, Lijia Cui, Xu Jiang, Ou Wang, et al.

    Context: Nearly 20% patients with tumor-induced osteomalacia (TIO) experienced recurrence or nonrecovery after surgery. Serum fibroblast growth factor 23 and phosphate concentrations are not sufficient for prognosis in such cases. Despite its importance for understanding of prognosis and underlying pathogenesis, the alteration of systemic metabolism in refractory TIO remains unclear. Objective: We aimed to find the metabolomic characteristics of refractory TIO and establish a novel predictive model for early discriminating refractory TIO based on their serum metabolomics. Design and setting: Cross-section study for comparison of metabolomic profile between TIO and normal control and longitudinal study for identifying prognostic model. Methods: Based on liquid chromatography-tandem mass spectrometry, we analyzed the global metabolomes of preoperative sera from 86 samples (32 TIO recovery patients, 11 nonremission patients, and 43 matched controls). Statistical analyses, pathway enrichment, and receiver operating characteristic analysis were performed to identified and evaluate potential markers. Results: Sparse partial least squares discriminant analysis indicated a clear separation of metabolomic profiles between healthy controls (HC) and TIO patients. The serum metabolites altered in different prognostic groups. L-pipecolic acid, 2-dodecylbenzenesulfonic acid, and 2-deoxygalactopyranose were the top 3 metabolites that were significantly perturbed. A combination of L-pipecolic acid and 2-dodecylbenzenesulfonic acid demonstrated a high-performance panel for TIO prognosis evaluated by random forest algorithm (area under the curve = 0.921, 95% CI, 0.787-0.995). Conclusions: We investigate the global metabolomes of refractory TIO and identify potential prognostic biomarkers preliminarily. A high sensitivity and specificity panel were identified as promising discriminating predictors, which need to be verified in more patients. This work may demonstrate novel insights into TIO prognosis and pathogenesis.


  • The First Compound Heterozygous Mutations ofDMP1Causing Rare Autosomal Recessive Hypophosphatemic Rickets Type 1

    by Xiaolin Ni, Yiyi Gong, Yan Jiang, Xiang Li, Qianqian Pang, Wei Liu, Yue Chi, Ruizhi Jiajue, Ou Wang, Mei Li, et al.

    Context Hereditary hypophosphatemic rickets (HR) consists of a group of inherited hypophosphatemia due to mutations of different genes, which needs genetic analysis to make differential diagnosis. Among them, autosomal recessive hypophosphatemic rickets type 1 (ARHR1) caused by homozygous mutation of dentin matrix protein 1 (DMP1), is extremely rare only with 30 reported patients. To date, there has been no case with compound heterozygous DMP1 mutations. Objectives, Design, Setting and Participants In this study, we reported the clinical features of a Chinese patient with HR. Whole exome sequencing (WES) was performed on the proband. Then, Cytoscan HD array, Sanger sequencing, and genomic quantitative PCR (qPCR) were used to confirm the mutations. Cell experiment was conducted to explore the effect of the mutation. Results The proband is a 4-year-old boy, who developed genu varum when he was able to walk at 1 year old and tooth loss after mild hit at 3.5 years old. Physical examination, biochemical measurement and imaging finding indicated HR. Family history was negative. WES performed on the proband revealed a novel start codon mutation (c.1A > T, p.Met1Leu) in DMP1 and a large deletion involving most of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family gene, including DSPP, DMP1, IBSP, and MEPE. The novel paternally inherited start codon mutation, which resulted in decreased expression of DMP1 protein with smaller molecular weight and cleavage defect, was confirmed by Sanger sequencing. The maternally inherited deletion was validated by Cytoscan and qPCR, and the breakpoint was finally identified by long-range PCR and Sanger sequencing. Manifestation of dentin dysplasia (DD) or dentinogenesis imperfecta (DGI) caused by DSPP mutations was absent in the patient and his mother, confirming that haploinsufficiency could not lead to DD or DGI. Conclusions We firstly reported compound heterozygous DMP1 mutations consisting of a large deletion and a novel start codon mutation (c.1A > T, p.Met1Leu) in a Chinese patient with ARHR1.